# Dear Dave

Dave and other members of the bpac<sup>nz</sup> team answer your clinical questions

If you have a clinical question email it to

dave@bpac.org.nz

### **Dear Dave**

## Is there an association between the use of the combined oral contraceptive and reduced Vitamin $\mathbf{B}_{12}$ deficiency

Contributed by Linda Bryant MClinPharm FPSNZ Clinical Advisory Pharmacists Association (CAPA)

The reduction in serum

Vitamin B<sub>12</sub> in women

using the combined oral

contraceptive is not

usually clinically significant

as vitamin metabolism

and stores are normal.

Further investigations are

warranted if there are signs

and symptoms suggestive

of deficiency or other

factors such as diet.

An association between use of the combined oral contraceptive and reduced Vitamin  $B_{12}$  serum concentrations has been noted since  $1969^1$ , but the clinical significance of this is debated.

Mean serum  $B_{12}$  concentrations may be 33–40% lower in women using the combined oral contraceptive compared to non-users<sup>2,3</sup>. One study of 71 women using low dose (20 micrograms ethinyl estradiol) oral contraception vs. 170 control non-users found that 13% of combined oral contraceptive users had Vitamin  $B_{12}$  concentrations less than 130 pmol/L compared to none in the control group; 15% had subnormal Vitamin  $B_{12}$  concentrations (130–170 pmol/L) compared to 4% in the non-users; and 72% had normal Vitamin  $B_{12}$  concentrations compared to 92% of the non-users.<sup>4</sup> Another study found 50% of combined oral contraceptive users have serum  $B_{12}$  concentrations less than normal (< 170 pmol/L) and 15% were clearly deficient (< 70 pmol/L).



Despite apparent low serum  $\rm B_{12}$  concentrations in some users of the combined oral contraceptive, clinical symptoms and macrocytosis are rare and tend only to be reported as case studies.<sup>5</sup> An early study of 201 cases of megaloblastic anaemia found only one case to be associated with oral contraceptive use.<sup>6</sup>

It is now accepted that the reduced serum  $B_{12}$  concentrations observed in OC users do not usually represent a true deficiency as absorption, excretion and stores of Vitamin  $B_{12}$  are usually normal. In addition, metabolic markers for deficiency (methylmalonic acid and homocysteine) remain unchanged and clinical symptoms are rare.<sup>6</sup>

It is postulated that the low serum  $B_{12}$  is due to a reduction in Vitamin  $B_{12}$  binding proteins in serum. In particular it may be due to reduced haptocorrin, the major binding protein for Vitamin  $B_{12}$ , although the mechanism is still unknown and under investigation.<sup>6</sup>

The reduction in serum  $B_{12}$  in women using the combined oral contraceptive is not usually clinically significant as vitamin metabolism and stores are normal. Further investigations are warranted if there are signs and symptoms suggestive of deficiency or other factors such as diet.

#### References

- Hjelt K, Brynskov J, Hippe E, Lundstrom P, Munck O. Oral contraceptives and cobalamin (Vitamin B<sub>12</sub>) metabolism. Acta Obstet et Gynecol Scand. 1985;64:59-63
- Green T, Houghton L, Donovan U, Gibson R, O'Connor D. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J Am Diet Assoc. 1998;98:49-55
- 3. Wynn V. Vitamins and oral contraceptive use. Lancet. 1975; 1(7906):561-4
- Sutterlin M, Bussen S, Rieger L, Dietl J, Steck T. Serum folate and Vitamin B<sub>12</sub> levels in women using modern oral contraceptives (OC) containing 20 micrograms ethinyl estradiol. Eur J Obstet Gynecol Reprod Biol. 2003;107:57-61
- Kornberg A, Segal R, Theitler J et al. Folic acid deficiency, megaloblastic anaemia and peripheral polyneuropathy due to oral contraceptives. Isr J Med Sci. 1989;23:142-5
- Bor M. Do we have any good reason to suggest restricting the use of oral contraceptives in women with pre-existing Vitamin B<sub>12</sub> deficiency? Eur J Obstet Gynecol Reprod Biol. 2004;115:240-1

## TOMORROW'S TECHNOLOGY, TODAY

bestpractice, the exciting new electronic Decision

Support from BPAC Inc, provides up to date clinical support for patient management, with a wide range of clinical modules based on current New Zealand guidelines and best practice.

